Podcasts about sofinnova partners

Timestamps:7:29 - How does the Swiss ecosystem compare to others?18:09 - Which Swiss scaleups is Nicolas excited about?23:46 - Does Swiss shyness hold us back?30:23 - Investing in companies with long development cycles35:08 - Creating outbound investment opportunities This episode was co-produced with the Deep Tech Nation Switzerland Foundation.Get started with Bitcoin by downloading the Relai app today. Click here to profit from 10% less fees by entering code SWISSPRENEUR at checkout.(Disclaimer: Relai services are exclusively recommended for Swiss and Italian residents.)About Nicolas Autret:Nicolas Autret is a partner at Walden Catalyst Ventures, a venture capital firm helping early stage companies in the US, Europe, and Israel build the next generation of category-defining businesses in deep tech. He holds an MBA from INSEAD and was previously a partner at Sofinnova Partners, 360 Capital and Samsung Catalyst Fund before joining Walden Catalyst in 2021.During his chat with Merle, Nicolas explained why he thinks the Swiss ecosystem should not try to replicate the Silicon Valley phenomenon. According to Nicolas, Silicon Valley is a unique ecosystem that's been around for 60 years, which resulted from a unique recipe for collaboration between academia, investors, entrepreneurs and large corporates. It took decades to mature, first through government funding and then later largely through private funding. The success of Silicon Valley ought to inspire us, says Nicolas, and of course best practices can be derived from it, but we should not try to replicate the exact same phenomenon in Switzerland — a very different country with its unique set of circumstances. Switzerland benefits from excellent universities and is quite strong in terms of deep tech, but it is still maturing as an ecosystem, as are other European startup hubs. Our culture of high performance and high precision differentiates us from the Americans and their “break things” mentality, but this is not necessarily a bad thing. Each mindset has its own individual perks.Nowadays, Nicolas is excited about Swiss companies like Scandit, ANYbotics, Ecorobotix and SOPHiA GENETICS. He thinks one major key to accelerating the maturation of the Swiss startup ecosystem (and other European ecosystems) is to allow for more late stage funding.The cover portrait was edited by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.smartportrait.io⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.‍Don't forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠and ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly giveaways or founders' dinners.

European venture firm Sofinnova Partners is expanding the reach of its Biovelocita accelerator beyond Italy to stretch across the greater continent. On the latest BioCentury This Week podcast, BioCentury's editors discuss how Biovelocita became the largest life sciences accelerator in Europe. The editors also discuss Novo Nordisk's latest addition to its obesity pipeline via a deal in China, and how the partnership reflects the state of cross-border dealmaking more broadly. And Washington Editor Steve Usdin assesses President Trump's threat to impose 25% tariffs on pharmaceutical imports and provides an update on how FDA's staff is navigating the policies of the new administration. Finally, Editor in Chief Simone Fishburn discusses BioCentury's upcoming Grand Rounds meetings.View full story: https://www.biocentury.com/article/65543800:00 - Introduction02:25 - Sofinnova's Pan-European Accelerator08:27 - China Biotechs14:59 - Trump TariffsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Joško Bobanović of Sofinnova Partners speaks about bioeconomy, industrial biotech, and biomanufacturing. Adam Lawrence co-hosts. OUTLINE (00:00) Introduction (00:34) Education and career path (02:21) Sofinnova Partners (04:28) Investment strategy (06:34) Terminology (08:45) Industrial biotech history and evolution (14:06) Competitive strategies for bio startups (16:55) End applications – fuels, food, pharmaceuticals, materials (21:23) Value ecosystem and participants (24:57) Drivers (27:15) Business models, platforms, products (33:05) Success stories (36:17) Future of industrial biotech and bioeconomy

Thomas Laurent's story is one of resilience, adaptability, and learning through experience. From his early days in Lyon, France, to leading Micropep Technologies as a pioneer in sustainable agriculture, he has gained valuable insights into entrepreneurship, leadership, and innovation. Thomas' latest venture, Micropep, has attracted funding from top-tier investors like Corteva Agriscience, Sofinnova Partners, Denis Lucquin, and Sparkfood.

Nos acompaña Cure51,una empresa de biotecnología que investiga los mecanismos biológicos responsables de la supervivencia en pacientes con cáncer de alto riesgo. Cure51 fue fundada en marzo de 2022 por Nicolas Wolikow y Simon Istolainen, junto con varios emprendedores como la doctora Paloma Cejas, experta en investigación medica en los hospitales de La Paz (Madrid) y Dana Farber (Boston), y cuatro centros de oncología de renombre mundial: Vall d'Hebron Instituto de Oncología (Barcelona - España), dos mas uno en París y otro en Lyon y otro en Berlín – Alemania.... Este año han obtenido una financiación semilla de 15 millones de euros que le permitirá , analizar e identificar los procesos moleculares que explican cómo unos pacientes con cáncer sobreviven durante periodos de tiempo muy prolongados a pesar de tener formas muy agresivas de la enfermedad. Esta compañía emplea las técnicas moleculares más punteras y colabora estrechamente con destacados centros oncológicos de todo el mundo entre los que se encuentran en el Vall d'Hebron Instituto de Oncología (VHIO). La compañía investiga cómo aprovechar esta nueva base de conocimiento para la medicina de precisión y desarrollar nuevos fármacos. La operación ha sido liderada por Sofinnova Partners, empresa europea de capital riesgo líder en ciencias de la vida, y cuenta con la participación de varios inversores como Hitachi Ventures GmbH, Life Extension Ventures, el magnate francés Xavier Niel y Olivier Pomel, CEO y cofundador de Datadog. Paloma Cejas, Cofundadora y directora de Investigación Traslacional de Cure51.

Pierluigi Paracchi, CEO e co-founder di Genenta Science (NASDAQ:GNTA) e moderatore del tavolo di lavoro per l'internazionalizzazione delle industrie nel settore delle biotecnologie voluto dal Ministro Tajani, ha oltre 20 anni di esperienza nel settore del venture capital. È stato Founder e CEO di Quantica SGR, Co-founder di Axòn Capital e AurorA Science, precedentemente Venture Consultant a Sofinnova Partners. Paracchi è stato inoltre investitore e Board Member di Ethical Oncology Science, acquisita nel 2013 per oltre 400 milioni di dollari. È Co-founder e Non-executive Director di Altheia Science, società operante nel settore delle malattie autoimmuni e Non-executive Chairman di Lipogems International, attiva nei medical device per processare il tessuto adiposo. Pierluigi, membro del comitato esecutivo di Federchimica Assobiotec, l'associazione italiana per lo sviluppo delle biotecnologie oltre a essere membro del direttivo di InnovUp, associazione no profit che unisce startup, scaleup, PMI innovative, innovation center, incubatori e acceleratori. Protagonista della 18° edizione del BioInItaly Investment Forum, che organizza Assobiotec: evento che vuole mettere in connessione le startup biotech nazionali con investitori internazionali per lo sviluppo del settoreDal 2008, BioInItaly Investment Forum è il principale forum di investimento per l'innovazione nel campo delle biotecnologie e delle scienze della vita in Italia. L'evento mira a far incontrare imprese e progetti innovativi in cerca di capitali con investitori finanziari e aziendali provenienti da tutto il mondo. Nel corso di due giorni, le startup selezionate da un panel di coach ed esperti presenteranno i loro progetti a investitori, aziende e attori dell'ecosistema dell'innovazione. Dal suo lancio, l'evento leader in Italia per l'innovazione biotecnologica ha contribuito ad attrarre investimenti per oltre 43 milioni di euro per 15 innovativestart-up. Nel corso degli anni il progetto ha inoltre selezionato e formato oltre 130 start-up finaliste, mettendole in contatto con 1.600 imprese e investitori.Siti, app libri e link utiliAssobiotec Genenta ScienceBioInItaly Investment Forumlibri da scegliereLa formazione per start up biotechI percorsi per la formazione per start up biotech e per andare incontro a esigenze del mercato degli investimenti sono i più vari e dipendono dal ruolo che si assume nel team della nuova impresa. Ci sono università e scuole superiori di management e corsi universitari, in tutti i settori dal medicale al biomedicale al finance. Lato soft skills, ci vuole una naturale propensione al rischio, un piacere nell'affrontare l'ignoto. E il mercato ha bisogno di queste professionalità, dal ricercatore al manager. Come anche delle start up nel Biotech. Negli ultimi cinque anni sono stati investiti 7,5 miliardi di euro sul mercato italiano del private equity e venture capital nei settori del medicale e delle biotecnologie , distribuiti su 500 operazioni. E' quanto è emerso in merito allo scenario italiano del private equity, venture capital e private tracciato da Alessia Muzio, Head of Research di Aifi, durante il BioInItaly Investment Forum, 18° edizione dell'evento organizzato da Federchimica Assobiotec che vuole mettere in connessione le startup biotech nazionali con investitori internazionali per favorire lo sviluppo del settore.

Panel discussion #3: Data-driven discovery: transforming healthcare with AI and Big DataModerated by Edoardo Tedeschi, Partner, Simmons & Simmons Embark on a journey through the digital revolution transforming healthcare and life sciences. Our panel of visionaries will unveil how Big Data and AI are not just buzzwords but pivotal tools reshaping the efficiency and efficacy of the sector. From predictive analytics to personalised medicine, learn how these technologies are revolutionizing care delivery, speeding up drug development, and creating smarter, patient-centric healthcare ecosystems. Witness the future as we explore the power of data and AI to heal, innovate, and thrive.Speakers:·       Fabio Caramelli, Space Rider Payload and Exploitation, Directorate of Space     Transportation, European Space Agency·       Stefano Carosio, Executive Director, Stam ·       Luca Emili, CEO and founder, Insilico Trials·      Javier Nunez-Vicandi, Principal, Digital Medicine Strategy, Sofinnova Partners

We're in San Sebastián 

In der Rubrik “Investments & Exits” begrüßen wir heute Otto Birnbaum, General Partner von Revent. Otto bespricht die Finanzierungsrunde von Upvest, Carbon Equity, Bon Vivant und die Fusion von General Catalyst und La Famiglia.Der deutsche Frühphasenfonds La Famiglia, bekannt für Investitionen in Unternehmen wie Personio und Deel, schließt sich mit dem US-amerikanischen Risikokapitalgeber General Catalyst zusammen, der auch in Airbnb investiert hat. Diese seltene Fusion in der VC-Welt zeigt das verstärkte Engagement eines der größten und aktivsten US-Investoren in Europa, da die Bedeutung des Technologie-Ökosystems der Region global zunimmt. Jeannette zu Fürstenberg, Gründungspartnerin von La Famiglia, wird Managing Director bei GC und übernimmt eine ähnliche Position wie ein General Partner, um ein globales Seed-Investmentprogramm aufzubauen. Das Berliner FinTech Upvest hat eine Partnerschaft mit dem US-Vermögensverwalter Blackrock bekanntgegeben, um zukünftig mit institutionellen Kunden von Blackrock zusammenzuarbeiten. Gleichzeitig hat Upvest in einer Finanzierungsrunde 30 Millionen Euro eingenommen und seine Bewertung auf einen "mittleren dreistelligen Millionenbetrag" erhöht. Diese Partnerschaft ermöglicht Upvest, die Infrastruktur für andere FinTechs bereitzustellen, die ihren Kunden Investitionen in Kryptowährungen, Aktien oder ETFs anbieten möchten. Durch die Zusammenarbeit mit Blackrock hofft Upvest, die Distanz zwischen FinTechs und Banken zu verringern und das Vertrauen zu stärken, während sie weiterhin ihren Fokus auf die Europäische Union richten und langfristig die Gewinnzone anstreben.Carbon Equity mit Sitz in Amsterdam, hat erfolgreich 6 Millionen Euro in ihrer Series-A-Finanzierungsrunde aufgebracht. Diese wurde von BlackFin Capital Partners angeführt und erhielt Beteiligung von 4Impact, einem bestehenden Investor. Die Plattform bietet individuellen Anlegern die Möglichkeit, wegweisende Klima-Technologieunternehmen zu unterstützen, indem sie niedrige Mindestzugangsgebühren für erstklassige Climate-Venture-Capital- und Private-Equity-Fonds anbietet. Die frischen Mittel sollen die europäische Expansion vorantreiben, Vertriebskanäle verbessern und den Weg für ihren ersten ELTIF-Fonds ebnen, der bereits ab 25.000 Euro zugänglich sein wird.Das französische Startup Bon Vivant, das sich auf die Herstellung authentischer Milch ohne Kühe mittels Bioreaktoren spezialisiert hat, hat in einer Seed-Finanzierungsrunde 15 Millionen Euro eingesammelt. Durch den Einsatz spezieller Hefekulturen produziert das in Lyon ansässige Unternehmen ähnliche Proteine wie in herkömmlicher Kuhmilch. Diese tierfreien Milchproteine sollen einen deutlich geringeren ökologischen Fußabdruck aufweisen. Die Finanzierungsrunde wurde von Sofinnova Partners und Sparkfood geleitet, unterstützt von Captech Santé und anderen Investoren. Das Unternehmen zielt darauf ab, seine Milchproteine bereits ab 2025 auf dem US-Markt zu vermarkten. 

Synopsis: Ram Aiyar, Ph.D., MBA, is the President & CEO of Korro Bio. Korro Bio harnesses the body's natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Having founded several companies, Ram talks about some of the non-obvious differences in terms of being senior leadership and founder of a company versus being CEO. He discusses his approach to fundraising and how it's changed over time. He talks about the field of RNA editing, the evolution of that space, and where he sees it heading long term. Finally, he discusses where the company is from a pipeline building perspective and how he thinks about indication selection. Biography: Ram Aiyar, Ph.D., MBA, is the chief executive officer and president of Korro Bio and sits on the board of directors. Ram brings nearly two decades of diverse experience in biotech and pharma, working across all stages of development from launch to clinical to commercialization. He has a long history of launching and building biotech startups, and previously held a wide range of roles in finance, strategy, product development and venture capital. Most recently, he was a co-founder, chief financial officer and chief business officer at Corvidia Therapeutics, and eventually led its acquisition by Novo Nordisk for $2.1B. Prior to Corvidia, he was an entrepreneur-in-residence at BioHealth Innovation (BHI). Ram started his scientific career in research at Janssen Pharmaceuticals' immunology group. He has also held leadership roles in corporate development, finance and strategy at FlowMetric Inc., Sofinnova Partners, and J.P. Morgan Chase. Ram received his M.S. and Ph.D. in electrical and computer engineering from Drexel University and an MBA in finance and business strategy from INSEAD (France/Singapore).

In this special feed drop hear the first episode of Emerging Medtech Today, hosted by Henry Peck and powered by LSI. The Emerging Medtech Today podcast offers a unique opportunity to gain valuable insights from industry leaders who are building breakthrough businesses that are moving medtech forward. Join Henry as he engages in captivating conversations with innovators and investors who are at the forefront of medtech. Discover the strategies, technologies, and ideas that are shaping the future of healthcare.  In this episode Henry Peck speaks with Diana Saraceni and Alessio Beverina, co-founders and managing directors of Panakes, a venture capital firm that's helping to build the next generation of game-changing technologies companies in the field of Life Sciences. Diana brings 23 years of venture capital experience and previously co-founded another successful venture capital firm called 360 Capital. Alessio, with an engineering background, co-founded Panakes in 2015 after working as a research engineer at Sofinnova Partners. Throughout the episode, Diana and Alessio provide valuable insights into the evolving landscape of medtech investing, shedding light on the complexities, challenges, and opportunities in the field. Topics include: Current market conditions and challenges faced by companies in medtech Key learnings from Panakes' first fund which focused on medtech and raised €75 million Strategies for the newly raised second fund, with plans to expand its focus to include biotech and opportunities where medtech and biotech converge The impact of regulatory changes, particularly the MDR (Medical Device Regulation) shift and the increasing prioritization of FDA approval in Europe   Navigating the evolving landscape of digital health and its intersection with artificial intelligence (AI) Health tech and digital health opportunities in Europe compared to the US A reflection on the future of healthcare innovation Diana and Alessio's upcoming participation at the LSI Europe ‘23 conference in September, where they will discuss these topics in greater detail And more! Transcript of episode Guest links and resources: Connect with Diana Saraceni: LinkedIn Connect with Alessio Beverina: LinkedIn | Twitter Panakes Connect with Henry: Twitter | LinkedIn Learn more about LSI Sign up for LSI Europe '23 Connect with LSI: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Connect with Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Cet épisode est rendu possible avec la nouvelle formation Demian "Parler en public avec aisance". Jusqu'au 2 juillet vous bénéficiez de -20% sur la formation avec le code "PAROLE20". Plus d'infos iciAujourd'hui je suis très heureuse de recevoir Jean Schmitt pour ce nouvel épisode.Au-delà d'être un ami, et une personne que j'admire énormément, Jean est investisseur chez Gemmyo, mais ce n'est pas son plus grand fait d'armes.Son plus grand fait d'armes c'est qu'il est entrepreneur et investisseur.Il a été PDG, fondateur de quatre sociétés dès la sortie de son école d'ingénieur avec, à chaque fois, des sorties réussies. On en parle évidemment dans cet épisode.Après ça il est devenu investisseur et a été associé Directeur chez Sofinnova Partners, dirigeant de la partie informatique en se concentrant sur les marchés de la télécommunication.Puis en 2012, Jean décide de se relancer à nouveau dans l'aventure entrepreneuriale et fonde Jolt Capital, son propre fond d'investissement, dont il devient président et associé Directeur.La caractéristique de Jolt Capital c'est qu'elle est consacrée aux entreprises de Deep Tech, de produits réellement innovants et qui cherchent à créer un maximum de valeur. Cela peut être des innovations de rupture comme l'intelligence artificielle, la reconnaissance faciale, etc… qui vont avoir un maximum d'impact sur l'économie.J'ai adoré cet épisode avec Jean pour plusieurs raisons : déjà parce qu'on est rentré dans le dur comme vous allez le voir. Et que d'autre part, ce que j'adore avec Jean c'est qu'il n'a pas sa langue dans sa poche. Peut-être allez-vous être un petit peu chahuté par ses propos.Mais je trouve que c'est assez sain d'avoir des débats profonds, des débats vrais, sans trop de circonvolutions.Je remercie Jean pour sa grande honnêteté intellectuelle et le fait de ne pas avoir peur d'exprimer ses opinions.Notes et références de l'épisode :Pour retrouver Jean Schmitt :Son site : Jolt CapitalLinkedInLivres cités dans l'épisode :Henri IV de Jean-Pierre BabelonRegain de Jean GionoDans la classe de Alain Amariglio1. Faites vous coacher par moi !DEMIAN, un concentré de 10 ans d'expérience d'entrepreneur. Les formations DEMIAN vous apportent des outils et méthodes concrètes pour développer votre projet professionnel. Il s'agit d'un concentré maximal de valeur et d'expérience pour qu'en quelques heures vous gagniez l'équivalent d'années de travail. Découvrez DEMIAN !2. La NewsLa News du vendredi est une mini newsletter pour vous nourrir en plus du podcast. C'est une newsletter très courte, à lire en 5mn top chrono de ce qui m'a marqué dans les dernières semaines : livres à lire, réflexions, applis à télécharger, citations, films ou documentaires à voir etc. Pour la recevoir, il n'y a qu'à s'abonner à la newsletter sur mon site !3. Des conseils concrets sur ma chaîne YouTubeEnvie de lancer votre propre podcast ? De bénéficier de conseils sur quel matériel utiliser ? Ma nouvelle chaîne YouTube est faite pour vous !4.Contactez-moi ! Si le podcast vous plaît, le meilleur moyen de me le dire, ou de me faire vos feed-backs (et ce qui m'aide le plus à le faire connaître) c'est simplement de laisser un avis 5 étoiles ou un commentaire sur l'application iTunes. Ça m'aide vraiment, alors n'hésitez pas :)Pour me poser des questions ou suivre mes tribulations c'est par ici :Sur Instagram @paulinelaigneauSur LinkedIn @pauline laigneauSur YouTube Pauline LaigneauVous pouvez consulter notre politique de confidentialité sur https://art19.com/privacy ainsi que la notice de confidentialité de la Californie sur https://art19.com/privacy#do-not-sell-my-info.

Anne Osdoit, PDG de Moon Surgical et Partner de Sofinnova Partners, était l'invité de François Sorel dans Tech & Co, ce mardi 16 mai. Elle a fait une présentation de Moon Surgical, notamment la croyance que l'avenir de la salle d'opération réside entre les mains du chirurgien "augmenté"sur BFM Business. Retrouvez l'émission du lundi au jeudi et réécoutez la en podcast.

Mardi 16 mai, François Sorel a reçu Frédéric Simottel, journaliste BFM Business ; Anne Osdoit, PDG de Moon Surgical et partner de Sofinnova Partners ; Teddy Pellerin, président et cofondateur de Heetch ; Fanny Bouton, responsable du programme startup d'OVHCloud ; Jean-Philippe Bertocchio, président de Skezi ; Alexandre Parpaleix, président et Directeur médical de Milvue ; Emilie Sidiqian, directrice générale de Salesforce France ; Sabrina Quagliozzi, correspondante à New York pour BFM Business ; Fatma Chouaieb, présidente de Hello Charly ; Stanislas De Zutter, cofondateur et président de Santé Académie ; Rodolphe Hasselvander, fondateur de Blue Frog Robotics ; Anne Thay, directrice générale adjointe de MOBiDYS France ; Michel Artières, PDG d'ATEME ; Julie Ragot, journaliste pour le site Tech&Co ; Aude Kersulec, journaliste BFM Business ; Nadia Benallal, déléguée générale de La French Tech Paris Saclay et Benoit Illy, président de Fairbrics, dans l'émission Tech & Co sur BFM Business. Retrouvez l'émission du lundi au jeudi et réécoutez la en podcast.

In this episode, Daniel Hawkins at Avail Medsystems and Duane Mancini discuss his background in the medical device industry, his time at Advanced Cardiovascular Systems (Abbot Vascular), Intuitive Surgical, his startup with the founder of Amgen, how he founded Shockwave Medical, his relationship with Antoine Papiernik at Sofinnova Partners, the proper way to challenge voice of customer, the support from Casey McGlynn at Wilson Sonsini Goodrich & Rosati, the investment @Shockwave received from Fred Moll at Intuitive Surgical, what he is doing at Avail Medical Systems, asking the right questions, Restore medical, staying the course, being very intentional about who you bring on your team, being mindful of your investors and board members, and so much more. Daniel Hawkins LinkedIn Avail Medsystems Website Project Medtech Website Project Medtech LinkedIn Duane Mancini LinkedIn

The world of health tech has changed dramatically since decades ago when physicians had to endure 11 keystrokes to prescribe a single aspirin. These days, AI-based radiology and AI-based pathology are transforming patient lives through machine learning and data analytics, in some cases offering early disease warning systems and improving quality of care while reducing healthcare costs.   In this episode of Back Bay's industry podcast, the Life Science Report, Jonathan Gertler speaks with Mikaela Odlander, Director of Digital Therapeutics at Orexo, and Edward Kliphuis, Partner at Sofinnova Partners, about the opportunities and challenges ahead in the realm of health tech and digital medicine.  Topics in this episode include:  - The misperceptions around digital therapeutics and digital medicine- The impact health tech has on care, fostering adoption, hurdles to reimbursement- The stark difference between the European and Nordic vs. US healthcare markets- Examples of AI machine learning and how digital medicine is providing personalized, efficient and effective healthcare- The major challenge of replication and scale for a company

In der Nachmittagsfolge sprechen wir heute mit Franz Pfister, CEO und Co-Founder von Deepc, über die erfolgreich abgeschlossene Series-A-Finanzierungsrunde in Höhe von 12 Millionen Euro.Deepc hat eine Plattform entwickelt, die es KI-Unternehmen ermöglicht, zertifizierte KI-Produkte effizient zu vermarkten. Für Krankenhäuser und Arztpraxen stellt die Plattform eine zentrale Anlaufstelle für sämtliche Anwendungen und Services im Bereich der KI-gestützten Radiologie dar. Die KI-Plattform DeepcOS ermöglicht den Einsatz von KI-Produkten für schnellere und genauere Diagnosen, was zudem auch zu besseren Behandlungsergebnissen führt. Deepc wurde im Jahr 2019 von Dr. Franz Pfister, Julia Moosbauer und Michael Meyerhoff in München gegründet. Die aktuell mehr als 40 Mitarbeitenden mit 20 verschiedenen Nationalitäten sorgen an sieben Standorten dafür, die KI-Usererfahrung für Radiologinnen und Radiologen zu verbessern und gleichzeitig den Marktzugang für KI-Softwareanbieter zu erleichtern.In einer Series A hat das KI-Startup nun 12 Millionen Euro unter der Führung der europäischen Risikokapitalgesellschaft im Bereich Life Sciences namens Sofinnova Partners eingesammelt. Simon Turner, Partner bei Sofinnova Partners, tritt im Rahmen der Finanzierung dem Board of Directors von Deepc bei. Bertelsmann Investments und der bestehende Kapitalgeber Winning Mindset Ventures sind ebenfalls an der Runde beteiligt. Das frische Kapital soll der geografischen Expansion sowie der Entwicklung zusätzlicher Funktionen der Plattform dienen. Radiologinnen und Radiologen sollen von neuen KI-gestützten Möglichkeiten profitieren, die nahtlos in ihre Arbeitsabläufe integriert werden, während KI-Softwareanbieter einen verbesserten Zugang zu einer großen Anzahl potenzieller Kundinnen und Kunden erhalten sollen.

Recorded at AWS & Wellington Partners “Health.Tech.Bio - Trends from Across the Pond” symposium at JPM, we welcome industry experts from the Israel Innovation Authority, Exscientia, Sofinnova Partners and Wellington Partners to share their insights on Europe's unique contributions to healthcare & life sciences innovation. Learn more about how AWS enables healthcare & life sciences startups to grow and thrive at https://aws.amazon.com/startups/ and https://aws.amazon.com/health/.

In this episode, our host Giovanni Lauricella and our guest Ronit Harpaz at Endoron discuss her background in the medical device space, how she raised money, grants and non-dilutive capital in Israel, the importance of raising enough capital and oversubscribing if necessary, their investment from Sofinnova Partners, and so much more. Ronit Harpaz LinkedIn Endoron Website Project Medtech Website Giovanni Lauricella LinkedIn Project Medtech LinkedIn

Today we are talking to Ram Aiyer. Ram is CEO of Korro Bio, an RNA base editing company focused on co-opting ADAR, a naturally present editing system in all our cells to base edit A to I (which is translated as a G) in RNA. Prior to Korro, Ram was CBO and CFO of Corvidia, a company he successfully helped build and sell to Novo Nordisk for 2.1Bn$. Prior to Corvidia he was an EIR at BioHealth Innovation. He started his scientific career at Janssen Pharmaceuticals and held leadership roles at FlowMetric, Sofinnova Partners, and JP Morgan Chase.Today we discuss his path to becoming the CEO of a biotech company, the transition for a first time CEO, his success at Corvidia, running a leading biotech company in today's markets and the science/technology & culture underpinning Korro. 

Dans ce numéro du journal des biotechs, le point d'actualité est consacré au partenariat récent conclu entre Sofinnova et Apollo, le géant américain du private equity. Cédric Moreau, partner chez Sofinnova était sur le plateau pour expliquer les conséquences de cet accord. L'entretien est consacré à Marc Delcourt, directeur général de Global Bioenergies alors que le groupe vient d'annoncer que plusieurs grands acteurs de la cosmétique, dont L'Oréal, ont passé leurs premières commandes pour un total de plusieurs tonnes d'Isonaturane 12, l'isododécane d'origine naturelle produit par Global Bioenergies. Le tout, moins de deux mois après la mise en service de l'unité de production commerciale de Pomacle.

Join DxTalks Interview with Mr. Edward Kliphuis, Partner, Sofinnova Partners,Part of PrecisionMed Exhibition & Summit, in Dubai on 24-25 May provides a unique opportunity for healthcare providers, academic scientists, and industry experts in this ecosystem to share knowledge and make connections.Under the patronage and presence of His Highness Sheikh Nahyan Bin Mubarak Al Nahyan, Cabinet Member and Minister of State for Tolerance of UAE & President of UAE Genetic Diseases Association.Book your place https://precisionmedexpo.com/The future of healthcare is personal, and it's precise.Interview by Rudy Shoushany ceo DxTalks, the Digital Leaders PlatformRudy Shoushany | Founder #DxTalks Digital transformation Talks and Podcastwww.DxTalks - The Digital Leaders Platform#PrecisionMed  #digitalhealth #healthtech

Join DxTalks Interview with Mr. Edward Kliphuis, Partner, Sofinnova Partners,Part of PrecisionMed Exhibition & Summit, in Dubai on 24-25 May provides a unique opportunity for healthcare providers, academic scientists, and industry experts in this ecosystem to share knowledge and make connections.Under the patronage and presence of His Highness Sheikh Nahyan Bin Mubarak Al Nahyan, Cabinet Member and Minister of State for Tolerance of UAE & President of UAE Genetic Diseases Association.Book your place https://precisionmedexpo.com/The future of healthcare is personal, and it's precise.Interview by Rudy Shoushany ceo DxTalks, the Digital Leaders PlatformRudy Shoushany | Founder #DxTalks Digital transformation Talks and Podcastwww.DxTalks - The Digital Leaders Platform#PrecisionMed  #digitalhealth #healthtech

The sale of a minority stake in Sofinnova Partners to PE firm Apollo will allow the European VC to grow while retaining its independence. Fresh off a conversation with Sofinnova's Antoine Papiernik, Associate Editor Stephen Hansen explains the 50-year-old firm's proactive approach to finding a partner among private equity firms and what's next for the firm now that it has more financial firepower. The podcast team also discusses the latest translational tidbits from BioCentury's Distillery, the first look at clinical data from the CRISPR-based gene editing platform of Caribou and how biopharmas are weighing their commitment to Russian patients against calls to disengage from the country.  This week's podcast is sponsored by MSD (Merck & Co. Inc. in the U.S.), whose London-based European Innovation Hub includes a business development and licensing team, clinical teams and its U.K. Discovery Research Centre.   For more information visit, msd.com/licensing. 

Industry's dueling headwinds of capital and talent are the focus of this year's Bio€quity Europe meeting, and in a special episode of BioCentury This Week, two veterans of the burgeoning Italian life sciences ecosystem, Sofinnova Partners' Graziano Seghezzi & Ambrosetti's Corrado Panzeri, say the country's biotech sector now has the capital and networks to weather the storm.

In this episode, I am joined by Luc Mathis, CEO of Meiogenix, a disruptive AgBiotech breeding company, helping Agriculture adjust to climate change and move away from adding chemicals to fields. Luc talks through his journey as a postdoctoral researcher to a start-up CEO position. Luc speaks candidly about the work-life challenges and traveling schedule that caused burnout. He outlined the importance of crucial mentors who helped him along the journey and talked about the mission and vision for Meiogenix, the disruptive technology, and his vision for a healthier agricultural and food system. We discussed the innovation opportunities and collaborations for the company, as well as the recent Series A successful funding round led by Sofinnova Partners

In this episode, our host Giovanni Lauricella and our guest Antoine Papiernik at Sofinnova Partners discuss the grit and time it takes to be a successful venture capital investor, his background with Sofinnova, what Sofinnova does and where they invest, why he invests in Medtech, Why Shockwave is his #1 Medtech story, the major differences between US and European investors, his thoughts on the MDR, the shift we are going to see in investors from around the globe looking at Medtech companies, why Sofinnova stands out, their most recent $548 million early-stage healthcare fund, and so much more. Antoine Papiernik LinkedIn Sofinnova Website Giovanni Lauricella LinkedIn Project Medtech LinkedIn Project Medtech Website

durée : 00:58:36 - Entendez-vous l'éco ? - par : Tiphaine de Rocquigny - En lançant sa start-up Theranos en 2003, Elizabeth Holmes comptait révolutionner les techniques de prélèvement sanguin en se passant d'aiguilles. Mais ses machines, pourtant commercialisées, n'ont jamais été fiables. L'ancienne bonne élève de la Silicon Valley en devient rapidement le mouton noir… - invités : Olivier Alexandre Sociologue, chargé de recherche au CNRS (Lip 6-CEMS/IMM); Antoine Papiernik investisseur, président de Sofinnova Partners

Joško Bobanović is a Partner, Industrial Biotechnology funds at Sofinnova Partners, a leading European venture capital firm in the life sciences. The focus of this group is finding companies that are applying the mature tools that were initially developed for healthcare into industrial disciplines, specifically, applications in food, chemicals, agriculture, and materials. Joško explains, "In the 20 years from then to now, we have shaved multiple zeros from the cost of sequencing. That's equally true for other areas of biotechnology. That shift has allowed us to open up the application from what we tend to call red biotech, red coming from the blood, in terms of healthcare, to other angles of biotech." "They often come in color-coded. You have the white biotech, green biotech, and blue biotech. The white one is industrial applications or products that are produced in the chemical industry. Then you have the green biotech, which focuses on and deals with plants. Then you have the blue biotech, which is oriented towards the ocean and typically focuses on algae and similar things. That's kind of how we look at biotech opportunities beyond just healthcare." @SofinnovaVC #SofinnovaPartners #IndustrialBiotechnology #IndustrialBiotech #DNAScript #Sustainability #Environmentalimpact sofinnovapartners.com Download the transcript here

Joško Bobanović is a Partner, Industrial Biotechnology funds at Sofinnova Partners, a leading European venture capital firm in the life sciences. The focus of this group is finding companies that are applying the mature tools that were initially developed for healthcare into industrial disciplines, specifically, applications in food, chemicals, agriculture, and materials. Joško explains, "In the 20 years from then to now, we have shaved multiple zeros from the cost of sequencing. That's equally true for other areas of biotechnology. That shift has allowed us to open up the application from what we tend to call red biotech, red coming from the blood, in terms of healthcare, to other angles of biotech." "They often come in color-coded. You have the white biotech, green biotech, and blue biotech. The white one is industrial applications or products that are produced in the chemical industry. Then you have the green biotech, which focuses on and deals with plants. Then you have the blue biotech, which is oriented towards the ocean and typically focuses on algae and similar things. That's kind of how we look at biotech opportunities beyond just healthcare." @SofinnovaVC #SofinnovaPartners #IndustrialBiotechnology #IndustrialBiotech #DNAScript #Sustainability #Environmentalimpact sofinnovapartners.com Listen to the podcast here

In this episode, Giovanni and Anne discuss Sofinnova and where they focus their investments, MD Start and the relationship between MD Start and Sofinnova, her new start-up company called Moon Surgical, being with something from inception through exit and how that math works from an investment side, and more. Anne Osdoit LinkedIn Sofinnova Website Giovanni Lauricella LinkedIn Project Medtech LinkedIn Project Medtech Website

In this episode, Giovanni and Anne discuss Sofinnova and where they focus their investments, MD Start and the relationship between MD Start and Sofinnova, her new start-up company called Moon Surgical, being with something from inception through exit and how that math works from an investment side, and more. Anne Osdoit LinkedIn Sofinnova Website Giovanni Lauricella LinkedIn Project Medtech LinkedIn Project Medtech Website

L'entretien est consacré à Cédric Moreau, partner chez Sofinnova Partners. Il explique notamment comment le financement des biotechs est en train de connaitre une évolution majeure, entre fonds de capital-investissement et de private equity. Il revient aussi sur deux participations du fonds Sofinnova Crossover : Gensight et Sensorion.

Dans ce numéro du Journal des biotechs, on fait notre point traditionnel sur les performances, le newsflow et les financements des biotechs françaises avec Sacha Pouget, fondateur de biotech Bourse L'entretien est consacré à Cédric Moreau, partner chez Sofinnova Partners. Il explique notamment comment le financement des biotechs est en train de connaitre une évolution majeure, entre fonds de capital-investissement et de private equity. Il revient aussi sur deux participations du fonds Sofinnova Crossover : Gensight et Sensorion.

We speak with Antoine Papiernik of European venture capital firm Sofinnova Partners about the closing of a new $550 million health care fund. Plus, Ian Balina of Token Metrics discusses what the first U.S.-listed Bitcoin futures ETF means for mainstream adoption of the cryptocurrency. And, the CEO of online ticket marketplace Vivid Seats on the company going public via a SPAC deal, and the state of the live events industry amid the pandemic.

Giovanni (Gio) Battistini, is Managing Director at the innovation venture company, Better Gambit LLC (https://www.bettergambit.com/). Gio is passionate about strategic and entrepreneurial innovation-driven business opportunities and has expertise in business development, strategic alliances, strategic investments, product development and commercialization, in both early stage startups and global corporations. Most recently, Gio served as Senior Vice President of the Ferrero company's Open Innovation Science, a global organization with the mission of driving the discovery, evaluation and integration of external science, technology and entrepreneurial innovations relevant to Ferrero (the Italian manufacturer of branded chocolate and confectionery products, and the second biggest chocolate producer and confectionery company in the world.) Prior to joining Ferrero, Gio was Global Vice President of Flavor Innovation Discovery at Firmenich, where he led the strategic discovery and commercialization of scientific innovations in the areas of taste modulation, health & nutrition, natural & sustainable, and breakthrough cost innovation. Prior to joining Firmenich, Gio was the co-founder and CEO of Zonebee, a spin-off from the University of Arizona, where he led a multi-disciplinary R&D team to create visionary technology to support informal learning and knowledge management. Gio has more than 25 years of experience in managing and taking to market innovative technology in several industries, both in Global 500 companies and early stage startups. Gio serves also as Strategic Advisor, Enzymit; Venture Advisor, Sofinnova Partners; and Alliance Partner, Green Swan Partners. Gio started his career at ABB Ltd, the Swedish–Swiss multinational corporation headquartered in Zürich, Switzerland, operating mainly in robotics, power, heavy electrical equipment, and automation technology areas. Gio has a MS in Electronic Engineering from Università di Pavia.

In this week's episode I am joined by Joško Bobanović, Partner at Sofinnova Partners, where he leads investments into Biotechnology enabled sustainable solutions across food, agriculture, materials and chemicals.  Joško reflects on his early journey, the important values and interests that helped him find his path as an investor into niche applications of Biotech. Joško talks about some of the big consumer and government changes that have helped shape  the marketplace and innovation opportunities. Joško compares and contrast's European and US markets, and outlines how sees the role of venture partner beyond just capital. He talks about being on a journey of constant learning, and about the growth and future outlook of the industry

On this Wednesday's #TheShot of #DigitalHealth Therapy, Jim Joyce and I got into topics with our guest that we never thought we would, even for a meticulously unproduced show. That guest today is the brilliant Edward Kliphuis who also speculated on him starting a new amazing job at Sofinnova Partners in just a few hours from now

Jeudi 17 juin 2021, LATE & SMART reçoit Antoine Papiernik (président, Sofinnova Partners) et Anne-Sophie Alsif (Cheffe économiste, BIPE)

Dans ce numéro du journal des biotechs, Sacha Pouget, directeur associé chez Kaliste Biotech Advisors et fondateur de Biotech Bourse vient faire le point sur le secteur : progression boursière, introductions en Bourse, financement. Les indicateurs sont pour le moment au beau fixe.

Dans ce numéro du journal des biotechs, Cédric Moreau, associé chez Sofinnova Partners explique comment la société de capital-investissement, référence du secteur des sciences de la vie, gère le contexte actuel. L'interview est consacrée à Stanislas Veillet, PDG de Biohyptis. La biotech spécialisée dans les pathologies du vieillissement annonce le lancement d'un essai avec son principal actif Sarconeos dans la luttre contre le Covid-19.